Shots:

• The US FDA grants the BDD for Elecsys GDF-15 assay that is intended for measurement of Growth Differentiation Factor-15 (GDF-15) in cachectic patients aged≥18yrs. with solid tumors for treatment with Pfizer’s PF-06946860
• GDF-15 assay helps to identify patients suitable for innovative treatment addressing unintentional weight loss in cancer patients and may provide a precision medicine approach to identifying patients likely to respond to a GDF-15 treatment
• Elecsys GDF-15 is a quantitative serologic- two-incubation step ECLIA using the sandwich test format for the detection of GDF-15 in human serum

 ­ Ref: GlobeNewswire | Image: Roche